Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such as, but not limited to, hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention relates to methods for treating and/or preventing cardiovascular disorders in persons of Hispanic descent, particularly Mexican Americans, using compositions comprising nebivolol.
1 . A method of reducing morbidity or mortality associated with cardiovascular disease in a person of Hispanic descent comprising administering to the person a therapeutically effective amount of nebivolol or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 wherein the cardiovascular disease is selected from the group consisting of congestive heart failure, hypertension, pulmonary hypertension, myocardial and cerebral infarctions, atherosclerosis, atherogenesis, thrombosis, ischemic heart disease, post-angioplasty restenosis, coronary artery diseases, renal failure, stable, unstable and variant (Prinzmetal) angina, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, transient ischemic attacks, cerebrovascular accidents, restenosis, controlling blood pressure in hypertension, platelet adhesion, platelet aggregation, smooth muscle cell proliferation, pulmonary edema, vascular complications associated with the use of medical devices, wounds associated with the use of medical devices, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, thrombocytopenia and bleeding disorders.
3 . The method of claim 1 , wherein the cardiovascular disorder is hypertension.
4 . The method of claim 1 wherein the nebivolol is administered in an amount of from about 1 mg per day to about 40 mg per day.
5 . A method of claim 1 , wherein the person of Hispanic descent is a Mexican American.
6 . A method for improving NO release in a person of Hispanic descent in need thereof, comprising administering to the person a safe and therapeutically effective amount of nebivolol or a pharmaceutically acceptable salt thereof.
7 . The method according to claim 6 wherein nebivolol or a pharmaceutically acceptable salt is administered in an amount of about 1 mg per day to about 40 mg per day.
8 . A method according to claim 6 , wherein the person of Hispanic descent is a Mexican American.
9 . A method for improving exercise tolerance or for improving the quality of life in a person of Hispanic descent in need thereof, comprising administering to the person a therapeutically effective amount of nebivolol or a pharmaceutically acceptable salt thereof.
10 . A method according to claim 9 wherein nebivolol or a pharmaceutically acceptable salt thereof is administered in the amount of about 1 mg to about 40 mg per day.
11 . A method according to claim 9 , wherein the person of Hispanic descent is a Mexican American.
12 . A method of treating and/or preventing a cardiovascular condition in a person of Hispanic descent in need thereof, comprising administering to a subject a therapeutically safe and effective amount of nebivolol or pharmaceutically acceptable salt and at least one other active agent, sufficient to treat said condition.
13 . The method of claim 12 wherein the at least one other active agent is a cardiovascular agent.
14 . The method of claim 13 wherein the cardiovascular agent is selected from the group consisting of ACE inhibitors, ARB's, adrenergic blockers, adrenergic agonists, agents for pheochromocytoma, anti-arrhythmics, antiplatelet agents, anticoagulants, antihypertensives, antilipemic agents, antidiabetics, anti-inflammatory agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic agents, renin inhibitors, vasodilators, vasopressors, AGE crosslink breakers, AGE formation inhibitors, and mixtures thereof.
15 . The method of claim 13 wherein the cardiovascular condition is selected from the group consisting of congestive heart failure, hypertension, pulmonary hypertension, myocardial and cerebral infarctions, atherosclerosis, atherogenesis, thrombosis, ischemic heart disease, post-angioplasty restenosis, coronary artery diseases, renal failure, stable, unstable and variant (Prinzmetal) angina, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, transient ischemic attacks, cerebrovascular accidents, restenosis, controlling blood pressure in hypertension, platelet adhesion, platelet aggregation, smooth muscle cell proliferation, pulmonary edema, vascular complications associated with the use of medical devices, wounds associated with the use of medical devices, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, thrombocytopenia and bleeding disorders.
16 . The method of claim 13 wherein the cardiovascular agent is selected from the group consisting of ACE inhibitors, ARB's, and mixtures thereof.
17 . The method of claim 13 wherein the cardiovascular agent is an ACE inhibitor.
18 . The method of claim 13 wherein the cardiovascular agent is an ARB.
19 . The method of claim 13 wherein the cardiovascular agent is selected from the group consisting of AGE crosslink breakers, AGE formation inhibitors, and mixtures thereof.
20 . The method of claim 13 wherein the cardiovascular agent is a calcium channel blocker.
21 . A method of claim 12 , wherein the person of Hispanic descent is Mexican American.